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Abstract 26 
Tendon healing is complex to manage because of the limited regeneration capacity of tendon 27 
tissue; stem cell-based tissue engineering approaches may provide alternative healing 28 
strategies. We sought to determine whether human embryonic stem cells (hESC) could be 29 
induced to differentiate into tendon-like cells by the addition of exogenous bone morphogenetic 30 
protein (BMP)12 (growth differentiation factor(GDF)7) and BMP13 (GDF6). hESC (SHEF-1) 31 
were maintained with or without BMP12/13 supplementation, or supplemented with 32 
BMP12/13 and the SMAD signalling cascade blocking agent, dorsomorphin. Primary rat 33 
tenocytes were included as a positive control in immunocytochemistry analysis. A 34 
tenocyte-like elongated morphology was observed in hESC after 40-days continuous 35 
supplementation with BMP12/13 and ascorbic acid. These cells displayed a tenomodulin 36 
expression pattern and morphology consistent with that of the primary tenocyte control. 37 
Analysis of tendon-linked gene transcription in BMP12/13 supplemented hESC demonstrated 38 
consistent expression of COL1A2, COL3A1, DCN, TNC, THBS4, and TNMD levels. 39 
Conversely, when hESCs were cultured in the presence of BMP12/13 and dorsomorphin 40 
COL3A1, DCN, and TNC gene expression and tendon matrix formation were inhibited. Taken 41 
together, we have demonstrated that hESCs are responsive to tenogenic induction via 42 
BMP12/13 in the presence of ascorbic acid. The directed in vitro generation of tenocytes from 43 
pluripotent stem cells may facilitate the development of novel repair approaches for this 44 
difficult to heal tissue. 45 
46 
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Introduction 47 
Tendon is a major component of the musculoskeletal system (1) playing a vital role in force 48 
transmission between bone and muscle and enhancing joint stability (2). Acute trauma, overuse 49 
and ageing can lead to tendon injuries (3,4). Current treatments have limited capacity to achieve 50 
successful tendon healing since the tissue is poorly vascularized, and scar tissue or fibrous 51 
adhesions often develop during the healing process (5). Treatment can involve many different 52 
types of surgical intervention, such as xenograft or allograft to treat large tendon defects, but 53 
potential problems with this method (such as foreign body reaction) can occur (3). A lack of 54 
adequate strategies for tendon repair has led to the development of engineered replacement 55 
tendon tissue for use in surgical implantation (4). Stem cell based intervention may provide new 56 
strategies for tendon repair. Embryonic stem cells (hESCs) are derived from human blastocysts 57 
and due to telomerase activity self-renew indefinitely. Effectively the cells are immortal in 58 
culture, a property unique amongst the cell types with potential in regenerative medicine 59 
applications, providing cells in unlimited numbers. Furthermore, they are pluripotent and 60 
accordingly can differentiate into cells of all three embryonic germ layers, namely mesoderm, 61 
ectoderm and endoderm (6) conferring upon them potential across the whole field of 62 
regenerative medicine. Consequently,they are favoured for tissue engineering in therapeutic 63 
applications both in vitro and in vivo (7–9). 64 
 65 
hESC are considered a valuable resource due to their intrinsic plasticity in differentiation 66 
capacity. However, there is a surprising paucity of research describing in vitro directed 67 
tenogenic differentiation of hESC. To date reports have favoured the engineering and rolling of 68 
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cell sheets derived from connective tissue growth factor (CTGF)-supplemented hESC-derived 69 
mesenchymal stem cells (hMSC) (10,11). These sheets then progress to display tendon-like 70 
morphological appearances, the expression of genes including SCX, COL3A1,  and DCN, but 71 
not TNMD (12). 72 
 73 
Bone morphogenic proteins 12 and 13 (BMP12/13, also known as GDF7/6) are members of the 74 
TGF-β superfamily, and have individually been shown to play important roles in chemotaxis, 75 
proliferation, matrix synthesis, and cell differentiation (13–17). BMP12 and/or BMP13 76 
promote tendon repair in rats and sheep (13,18,19). In addition, BMP12 has been reported to 77 
induce the in vitro and in vivo tenogenesis of MSCs (derived from a wide variety of sources 78 
including bone marrow, synovial fluid, adipose tissue) in dog, mouse, rat, rhesus monkey, 79 
human, horse and chicken (13,20–28). There are also reports describing a role for BMP12 in 80 
tenogenic differentiation of tendon stem cells derived from rat (29). However, to our 81 
knowledge, there are no descriptions of the use of BMP12 and/or BMP13 to direct 82 
differentiation of hESCs into tendon-like cells. In this study, we investigated whether hESCs 83 
could differentiate into tenocyte-like cells when supplemented with BMP12/13 and ascorbic 84 
acid (AA). Further, we sought to determine whether SMAD signalling was implicated in 85 
BMP12/13 induced changes via inhibition of the SMAD pathway, or whether other signalling 86 
cascades were involved in the hESC tenogenic process. 87 
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Materials and Methods 88 
Culture of Primary Rat tenocytes and hESCs 89 
Primary tenocytes were isolated from 8 week old Sprague-Dawley rats. The Achilles tendon 90 
was isolated, extracted, placed into a dry petri dish and allowed to adhere for 3 hours. Media 91 
was added, and the explant cultured for 7 days allowing for tenocyte migration and expansion 92 
in ambient oxygen (21% O2)/5% CO2 in high glucose Dulbecco’s Modified Eagle Medium 93 
(DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza), 1% non-essential 94 
amino acids (NEAA, Lonza), 1% L-glutamine (Lonza) and 1% penicillin, streptomycin and 95 
amphotericin B (PSA, Lonza). After 7 days, the rat tenocytes were washed twice with 96 
phosphate buffered saline (PBS, Lonza), trypsinised (1% Trypsin/EDTA (Lonza)/PBS 97 
solution), centrifuged for 3 minutes (200g), re-seeded into two T-25 culture flasks, and cultured 98 
until 70% confluent. Once 70% confluent, the tenocytes were again trypsinised, and re-seeded 99 
at 0.5 x10
3
 cells/cm
2
 onto 6 well plates and cultured for a further 48 hours before being fixed for 100 
immunocytochemistry. 101 
 102 
hESC were cultured according to the Matrigel substrate and mouse embryonic fibroblast 103 
(MEF)-conditioned media (CM) protocol (30). CM was obtained by placing Knockout 104 
(KO)-DMEM (Gibco), 20% Serum Replacent (SR) (Gibco), 1% NEAA, 1% L-Glutamine, 105 
4ng/ml bFGF (Peprotech) and 50mM -mercaptoethanol (Gibco) for 24 hours on 50-60% 106 
confluent MEFs. After 24 hours, the culture medium was removed, and 4ng/ml bFGF added 107 
prior to filtration. SHEF-1 hESCs were cultured in either ambient (21% O2) or physiological, 108 
low-oxygen (2% O2) conditions. Differentiation was performed in the 2% O2 condition only. 109 
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Tenogenic differentiation of hESCs 110 
SHEF-1 cells were seeded into 6-well plates at (2×10
3 
cells/cm
2
) in CM. After 24 hours CM 111 
was removed and replaced with differentiation media which consisted of KO-DMEM, 10% 112 
FBS, 1% NEAA, 1% L-glutamine, 50mM β-mercaptoethanol and 10mM AA (Sigma) with or 113 
without BMP12 (R & D Systems) and BMP13 (Peprotech) both at 10ng/ml. To evaluate the 114 
role of SMAD signalling in tenogenic differentiation, hESC were seeded and differentiated as 115 
above, with the exception that during differentiation hESC were further supplemented with 116 
1μM dorsomorphin (31,32) (Sigma). 117 
 118 
Reverse transcription PCR (RT-PCR) 119 
RNA was collected from undifferentiated hESC at Day 0, and subsequently at Days 5, 10 and 120 
20 in the presence of differentiation media in both 2% O2 and 21% O2. In addition to above 121 
RNA was collected from hESC in differentiation media supplemented with either BMP12/13 or 122 
BMP12/13/dorsomorphin supplementation at days 5, 10, 20 and 40. RNA was collected by first 123 
washing with PBS followed by the addition of cell lysis buffer (Qiagen), scraping, collection, 124 
and homogenisation with a QIAshredder spin column (Qiagen). RNA extraction was performed 125 
with the RNeasy Mini kit (Qiagen) following manufacturer’s instructions. RT-PCR was 126 
performed with Superscript III One-Step HiFi RT-PCR kit (Invitrogen) again following 127 
manufacturer’s instructions. The genes analysed were representative of a tenocyte-like 128 
phenotype and were COL1A2, COL3A1, DCN, TNC, TNMD and THBS4 (33), primers used are 129 
shown in Table 1. GAPDH level was used as an internal control. Electrophoresis was 130 
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performed on 2% agarose gel (Gibco) at 100V for 1 hour. Gels were imaged on the Syngene 131 
Gel UV illuminator. 132 
 133 
Immunocytochemical analysis 134 
Cells were fixed in 95% methanol for 15 minutes before being washed with PBS. Cells were 135 
permeabilised with 0.5% Triton-X for 5 minutes, washed with PBS, and incubated in a 3% 136 
albumin solution (Sigma) for 1 hour at room temperature. Primary tenomodulin antibody 137 
(C-terminus) (SC98875, Santa Cruz Biotechnologies, Germany, 1:500 dilution in PBS) was 138 
then added to each well followed by a 30 minute incubation at 37
o
C and PBS washes. 139 
Secondary antibody (SC2090 Santa Cruz Biotechnologies, Germany, 1:500 dilution in PBS) 140 
was then added to the appropriate wells followed by a further incubation at 37
o
C for 30 minutes, 141 
PBS washes, and DAPI (1:500 dilution, Sigma) counterstaining. Images were captured via 142 
appropriate filter sets on Nikon Eclipse T1 microscope using a Nikon DSi 1 camera. 143 
 144 
Histological analysis 145 
Alcian Blue staining 146 
Cells were fixed at Days 0, 2, 5, 10, 20 and 40 using 95% methanol for 15 minutes followed by 147 
PBS washes. Cells were then stained with Alcian blue (A3157-10G, Sigma Aldrich, UK) for 24 148 
hours at room temperature on an R100 Rotateck shaker (Luckham). After 24 hours, the Alcian 149 
blue solution was aspirated, and each well washed with sterile double filtered dH2O. Once all 150 
the excess Alcian blue stain had been removed, the plates were dried at room temperature 151 
before imaging on Nikon Eclipse TD100 inverted microscope. 152 
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Masson’s Trichrome Staining 153 
Wells were fixed at days 0, 2, 5, 10, 20 and 40 using 95% methanol for 15 minutes and washed 154 
twice with PBS. PBS was aspirated from the wells and Bouin’s Solution (Sigma) added to 155 
completely cover the well base before being placed on the R100 Rotateck shaker (Luckham) for 156 
24 hours. After 24 hours Bouin’s solution was aspirated and each well washed with double 157 
filtered H2O to remove residual Bouin’s solution. The wells were then counterstained with 158 
Haematoxylin (Sigma) for 5 minutes before washing as before and applying Biebrich 159 
Scarlet-Acid Fuschin solution (Sigma) for 5 minutes, washing again, and incubating in fresh 160 
phosphotungstic/phosphomolybdic acid solution (PT/PMA) (Sigma, 25% (
v
/v) PT, 25% PMA 161 
and 50% dH2O) for 5 minutes at room temperature. Following incubation in the PT/PMA 162 
solution and its removal aniline blue solution (Sigma) was added, and the samples incubated at 163 
room temperature for 5 mins before removal and incubation in 1% acetic acid at room 164 
temperature for a further for 2 minutes before washing again and air drying for 24 hours. 165 
Images were collected on a Nikon Eclipse TD100 inverted microscope with a. Canon EOS 166 
400D camera. 167 
Quantification 168 
Staining intesity of Alcian blue and Masson’s Trichrome stained images was semi-quantified 169 
using ImageJ (34)[31]. All images were acquired at low magnification with identical 170 
microscope and camera settings and were acquired from the centre of stained wells to avoid 171 
user bias. To ensure that only regions positively stained with Alcian blue were considered, 172 
RGB images were first colour separated using the ImageJ colour deconvolution algorithm 173 
reveloped by Ruifrok and Johnston, with colour vectors determined by region of interest as 174 
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previously described (35)[32]. For Masson’s trichrome staining, total image intensity was 175 
determined. 176 
Statistical Analysis 177 
The significance of difference between groups (n=6 per group) was determined by one-way 178 
ANOVA single factor one-tailed comparison analysis. A p value less than 0.05 was considered 179 
to indicate statistical significance. Data are presented as mean ± standard deviation (SD). All 180 
statistical analysis was performed using Minitab® 16 (Minitab Inc., Pennsylvania, USA). 181 
182 
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Results 183 
BMP12/13 stimulated the expression of tendon-linked gene expression in hESCs 184 
SHEF-1 cells cultured in a 21% O2 environment in differentiation media without BMP 185 
supplementation showed continued expression of GAPDH, COL1A2, and TNC over 20 days 186 
(Figure 1, Left panel). COL3A1 and DCN expression was apparent by Day 10 and thereafter 187 
whereas THBS4 displayed sequential downregulation over the 20 day timecourse. TNMD 188 
expression was not detected. Similarly, SHEF-1 cells cultured in 2% O2 environment in 189 
differentiation media without BMP supplementation again showed continued expression of 190 
GAPDH, COL1A2 and TNC over 20 days (Figure 1, Right panel). TNMD expression was noted 191 
on Day 5 only and COL3A1 and DCN on Day 10. In contrast to the observed expression pattern 192 
in 21% O2, THBS4 underwent sequential upregulation of expression in 2% O2. 193 
 194 
SHEF-1 treated with BMP12/13 over 40 days in 2% O2 resulted in continuous expression of 195 
GAPDH, COL1A2, COL3A1, TNC, and THBS4. DCN underwent an apparent upregulation over 196 
the first 20 days while TNMD expression was maintained to Day 20 and reduced thereafter 197 
(Figure 2A Left panel). Differentiation media supplemented with both BMP12/13 and 198 
dorsomorphin showed several distinct differences when compared to BMP12/13 supplemented 199 
differentiation media (Figure 2A ). COL3A1, DCN, and TNC all underwent substantial 200 
downregulation of expression, whereas COL1A2, THBS4, and TNMD transcripts displayed 201 
sustained expression throughout the timecourse. 202 
 203 
 204 
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BMP-12/13 induced tenomodulin expression in hESCs 205 
SHEF-1 cells cultured in BMP12/13 supplemented differentiation media displayed little or no 206 
tenomodulin protein expression over the first 20 days (Figure 2C). However, by Day 40 207 
differentiated cells displayed a distinct tenomodulin staining pattern (Figure 2C), consistent 208 
with the synapsing observed with the rat tenocyte positive control (Figure 2B). The addition of 209 
dorsomorphin to BMP12/13 supplemented differentiation media resulted in an absence of 210 
observable tenomodulin staining over the timecourse (Figure 2C). 211 
 212 
Histological staining and colorimetric quantification 213 
Alcian blue 214 
Tendon matrix is comprised primarily of collagen alongside a number of other matrix 215 
molecules including glycosaminoglycans (GAGs) (33). We next sought to determine the role of 216 
BMP12/13 in altering matrix composition towards a tendon-like GAG-rich composition. The 217 
histological stain Alcian blue revealed strong staining after 40 days differentiation vs. control 218 
cultures (Figure 3A). Visually Alcian blue positive regions appeared to associate into long, 219 
string-like, condensations which appeared to connect with each other. Primary rat tenocyte 220 
cultures (images included for observation) did not display histologically detectable GAG 221 
deposition in controls or in response to BMP12/13 supplementation and were therefore not 222 
quantified. Over 40 days untreated control hESC displayed an approximate 21% increase in 223 
positive labelling whereas samples incubated with BMP12/13 registered a 35% increase 224 
(Figure 4A). This indicated a spontaneous deposition of GAGs in control hESC cultures that 225 
was significantly augmented by BMP12/13 supplementation. Dorsomorphin addition to control 226 
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hESC cultures resulted in a complete blockage of GAG deposition, while its addition in the 227 
presence of BMP12/13 resulted in a 26% increase in GAG deposition over 40 days which was 228 
comparable to untreated control cells (Figure 4A). 229 
 230 
Masson’s Trichrome 231 
The primary component of tendon matrix is collagen. Masson’s trichrome is a convenient stain 232 
in the identification of collagen deposition. Differentiated hESCs revealed distinct cord-like 233 
patterning of collagen deposition after 40 days supplementation with BMP12/13 (Figure 3B). 234 
In contrast, control unsupplemented cultures displayed a diffuse faint relatively ubiquitous 235 
patterning. Primary rat tenocytes, again included for observation, displayed evidence of a 236 
distinct pattern of collagen deposition when compared to differentiated hESC. Over 40 days 237 
BMP12/13 supplementation resulted in a 51% increase in collagen deposition vs. 23% for 238 
control cultures (Figure 4B). Conversely dorsomorphin supplementation of control cells 239 
resulted in a complete block on collagen deposition which was only marginally improved to a 240 
10% increase in the presence of BMP12/13. 241 
242 
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Discussion 243 
In vitro tenogenesis is challenging, and the development of simple protocols for its induction 244 
will improve our understanding of tendon biology and the development of future therapies for 245 
tendon treatment. This study demonstrated, for the first time, that a growth supplement cocktail 246 
containing BMP12, BMP13 and AA can induce hESC in vitro tenogenic differentiation under 247 
physiologically normoxic (2% O2) conditions. Stable transcription of tendon-linked and 248 
specific genes was observed alongside deposition of a tendon-like matrix and elongated, 249 
synapsing, cells with concurrent tenomodulin expression. This represents a forward step in 250 
tenogenesis studies and will facilitate the generation of enhanced in vitro studies. 251 
 252 
The definition of a tenocyte is surprisingly complex. The most basic measure is cell phenotype 253 
where the tenocyte is reported frequently as being a long elongated cell which forms cell-cell 254 
connections via synapsing (36,37). Frequently panels of gene expression are used as an 255 
indicative phenotype measure. These can include the α-chains of collagens type I and III, DCN, 256 
TNC, and SCX, amongst others (33). In this study, we adopted TNMD and THBS4, alongside 257 
some of the above, following from the findings of Jelinsky et al (12). In their microarray based 258 
studies, they identified TNMD and THBS4 expression as best fitting the definition of tendon 259 
tissue specific in both human and rat tissue. Similar to their study no expression of SCX was 260 
noted. We also adopted cellular expression of the tenomodulin protein in association with 261 
synaptic linkage between cells as a measure of tenogenesis (38,39). A combined definition, 262 
drawn from previous publications, of a tenocyte could therefore be an elongated, synaptic, cell 263 
which expresses the genes TNMD and THBS4 and displays positive labelling for the 264 
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tenomodulin protein in association with cell-cell synapses. In agreement with this, the 265 
combined addition of BMP12, BMP13, and AA, to a basic hESC differentiation media resulted 266 
in a controlled hESC differentiation towards a tenogenic lineage.  267 
 268 
There are relatively few reports of supplement-directed tenogenic differentiation which allow 269 
comparisons to be made. SCX expressing, endogenous or ectopic, hESC-MSCs or 270 
hESC-Connective Tissue Progenitors (CTPs) were allowed to be become confluent before 271 
being rolled into a sheet and mechanically conditioned for application in an in vivo repair model 272 
(10,11,40,41). Histology and mechanical properties of in vitro and in vivo tissue was consistent 273 
with tendon, but tendon-linked marker gene expression was either lost after 2 weeks in situ or 274 
not explored post-transplant and suboptimal regeneration was frequently observed. 275 
 276 
BMP12 and BMP13 signalling are transduced by the BMP Type Ia receptor via 277 
receptor-regulated SMADS (SMAD1, 5 and 8) association with the common mediator, 278 
SMAD4, followed by complex translocation into the nucleus to activate gene transcription 279 
(20,29,42–45). BMP signaling has been suggested to be inhibitory to tendon development by 280 
decreasing the pool of available tendon progenitor cells and restricting tendon-linked gene 281 
expression (40). In this instance, and in agreement with studies documenting an association of 282 
BMP12 and/or 13 with tenogenesis (13,18,19,21–29,44), we noted that BMP12 and BMP13 283 
supplementation was required for maintenance of tendon-specific gene expression including 284 
TNMD and THBS4. Berasi et al similarly found sustained expression of THSB4 in response to 285 
BMP12/13 supplementation in ectopic tissue in a  rat model and a mouse mesenchymal cell 286 
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line with no evidence of SMAD1, 5 and 8 activation (46).  We noted that dorsomorphin, an 287 
inhibitor of BMP signaling, did not inhibit transcription of TNMD or THBS4, but did inhibit 288 
COL3A1, DCN, and TNC to some extent. This is suggestive of an alternative, BMP-signalling 289 
independent, control of tendon-specific gene expression. It is also notable that although TNMD 290 
gene expression was maintained in the presence of dorsomorphin the protein was virtually 291 
undetectable via immunofluorescence, indicating the likelihood of a BMP-signalling driven 292 
translational machinery or key factor in post-translational stability. A deficiency in 293 
extracellular structure or matrix composition was also apparent following on from 294 
dorsomorphin treatment, with significant reduction in matrix-associated GAG, collagen and 295 
elastin. Taken together, these data indicate a complex scenario of BMP signaling requirements 296 
in the development and maintenance of tendon gene expression and tendon tissue. 297 
 298 
In this study, we have demonstrated that hESCs are responsive to tenogenic induction via 299 
BMP12/13 and ascorbic acid supplementation at 2% O2. However, the mechanisms by which 300 
BMP12/13 maintain tendon-linked and tendon-specific gene expression and histology remain 301 
unclear, but appear to dissociate into BMP-dependent (COL3A1, DCN, TNC, tenomodulin 302 
immunofluorescence, tendon-like matrix) and BMP-independent (TNMD and THBS4). These 303 
results will help provide greater insight into BMP12/13 driven tenogenesis of hESC and new 304 
directions of exploration in the design of hESC based treatments for tendon healing. 305 
  306 
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Table 1. Tendon-linked gene expression panel. 455 
 456 
Gene  Primer (5’-3’) Annealing 
Temp (
o
C) 
Amplicon 
Size (bp) 
COL1A2 
F GACTTTGTTGCTGCTTGC 
50 242 
R CAAGTCCAACTCCTTTTCC 
COL3A1 
F AAGGACACAGAGGCTTCG 
51 210 
R CTGGTTGACCATCAATGC 
TNMD 
F GCACTGATGAAACATTGG 
47 274 
R ATCCAATACATGGTCAGG 
THBS4 
F CCCCAGGTCTTTGACCTTCTCCC 
59 245 
R ACCTTCCCATCGTTCTTCAGGT 
TNC 
F AAGAGCATTCCTGTCAGC 
50 217 
R CAGTTTGCCGGTAAGAGG 
DCN 
F CTGCTTGCACAAGTTTCC 
48 372 
R TTCCAACTTCACCAAAGG 
GAPDH 
F GAGTCAACGGATTTGGTCGT 
55 225 
R GATCTCGCTCCTGGAAGATG 
Gene names, primer pair sequences, annealing temperatures, and expected amplicon sizes are 457 
shown. 458 
 459 
 460 
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 461 
Figure 1. Tendon-linked gene expression in spontaneously differentiated hESC. Expression of 462 
RT-PCR amplified tendon-linked genes including COL1A2, COL3A1, DCN, TNC, THBS4, and 463 
TNMD is shown. GAPDH is included as an internal control. Primer sequences used are 464 
described in Table 1. The left-hand and right-hand panels indicate hESC spontaneously 465 
differentiating in 21% O2 and 2% O2, respectively, over days 0, 5, 10 and 20. 466 
  467 
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 468 
Figure 2. BMP12/13 supplementation and 2% O2 culture promotes stable tenomodulin 469 
expression. A) RT-PCR amplification of the tendon-linked genes described in Figure 1. The 470 
left-hand and right-hand panels indicate hESC differentiating in 2% O2 with media 471 
supplemented with BMP12/13 or BMP12/13 plus dorsomorphin, respectively at days 5, 10, 20, 472 
and 40. B) Immunofluorescence detection of characteristic tenomodulin protein expression in 473 
primary rat tenocytes. Tenomodulin is green, DAPI (nuclei) is blue. C) Immunofluorescence of 474 
fixed samples paired to A). Colours as described in B). Scale bar indicates 100µm. 475 
  476 
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 477 
Figure 3. Matrix compositional changes induced by BMP12/13 supplementation. A) Primary 478 
rat tenocytes (Top panels) and hESC (Bottom panels) with and without BMP12/13 479 
supplementation. Samples were fixed and stained with Alcian blue after 40 days in continuous 480 
culture without passaging. B) Samples matched to 3A) fixed and stained with Masson’s 481 
Trichrome. C) Representative image from BMP12/13 supplemented hESC (right hand panel) 482 
indicated shared morphological features with primary rat tenocytes (left hand panel). Scale bar 483 
indicates 200µm. 484 
  485 
27 
 
 486 
Figure 4. Dorsomorphin blocks BMP12/13 supplementation-induced matrix deposition in 487 
hESC. A) ImageJ driven analysis of Alcian blue-stained hESC differentiation over 40 days. 488 
Y-axis indicates % Blue Channel (RGB extraction) of randomly selected fields of view. X-axis 489 
indicates Time (days). Solid line indicates hESC, dotted line indicates hESC+dorsomorphin 490 
(Dorso), dashed line indicates hESC + BMP12/13, and hatched line indicates hESC + 491 
BMP12/13+Dorso. * indicates p<0.05 vs. hESC, ** indicates p<0.05 vs. hESC+Dorso, *** 492 
indicates p<0.05 vs. all. B) ImageJ driven analysis of Masson’s Trichrome-stained hESC over 493 
40 days differentiation. Y-axis indicates % Colour (RGB extraction) of randomly selected 494 
fields of view. X-axis indicates Time (days). Legend labelling is consistent with (4A) above. 495 
Error bars indicate standard deviations. n=5 at each time point. 496 
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